


Amendments to the Claims

1. (Original) A compound of the formula:




Formula I

wherein ,

Y represents CH₂ or O;

R1 and R2 each independently represent hydrogen or fluoro



R3 represents a group of the formula:



wherein Z represents (CH₂)_n or -CR₄R₅-CH₂-;

n represents 0-3; and


Het represents a group of the formula:



R4 and R5 each independently represent at each occurrence hydrogen or methyl;

R6 and R7 each independently represent at each occurrence hydrogen, methyl, or ethyl;

provided Formula I does not represent a compound selected from the group consisting of



or a pharmaceutically acceptable salt thereof.

- (Original) The compound according to Claim 1 wherein R¹ represents hydrogen.


3. (Original) The compound according to Claim 1 wherein R¹ represents fluoro.
4. (Previously Presented) The compound according to Claim 1 wherein R² represents hydrogen.
5. (Previously Presented) The compound according to Claim 1 wherein R² represents fluoro.
6. (Previously Presented) The compound according to Claim 1 wherein R³ represents a group of the formula:




wherein Z represents (CH₂)_n or -CR₄R₅-CH₂-;

n represents 0-3; and


Het represents a group of the formula:




7. (Original) The compound according to Claim 6 wherein Het represents a group of the formula:




8. (Original) The compound according to Claim 6 wherein Het represents a group of the formula:




9. (Previously Presented) The compound according to Claim 6 wherein R^3 represents a group of the formula:



10. (Original) The compound according to Claim 9 wherein R^3 represents a group of the formula:




11. (Original) The compound according to Claim 9 wherein R^3 represents a group of the formula:



12. (Previously Presented) The compound according to Claim 1 wherein R³ represents a group of the formula:



13. (Original) The compound according to Claim 12 wherein R³ represents a group of the formula:



14. (Previously Presented) A pharmaceutical composition comprising the compound according to Claim 1 in combination with a pharmaceutically acceptable carrier, diluent, or excipient.

15. (Cancelled)
 16. (Cancelled)
 17. (Cancelled)
 18. (Cancelled)
 19. (Cancelled)

20. (Previously Presented) The compound according to Claim 1 selected from the group consisting of 5-(3,7-Difluoro-6H-dibenzo[b,e]oxepine-11-ylidenemethyl)-1-(1-methyl-piperidin-4-yl)-1,3-dihydro-benzimidazol-2-one, E-isomer; 5-(3-Fluoro-6H-dibenzo[b,e]oxepin-11-ylidenemethyl)-1-(1-methyl-piperidin-4-yl)-1,3-dihydro-benzimidazol-2-one, E isomer; 5-(3,8-Difluoro-6H-dibenzo[b,e]oxepin-11-ylidenemethyl)-1-(1-methyl-piperidin-4-yl)-1,3-dihydro-benzimidazol-2-one, E isomer; (R)-5-(3-fluoro-6H-dibenzo[b,e]oxepin-11-ylidenemethyl)-1-[1-(1-methyl-2-morpholin-4-yl-ethyl)-piperidin-4-yl]-1,3-dihydro-benzimidazol-2-one, E isomer; and (R)-5-(3,7-difluoro-6H-dibenzo[b,e]oxepin-11-ylidenemethyl)-1-(1-methyl-pyrrolidin-3-yl)-1,3-dihydro-H-benzimidazol-2-one, E isomer.